ATC CODE
- L04AA13
INDICATIONS AND NEMLC RECOMMENDATIONS
INDICATIONS AND NEMLC RECOMMENDATIONS 1
INDICATION
- As add-on therapy in Rheumatoid Arthritis.
NEMLC RECOMMENDATION
- Approved - Special Acess
Special access be permitted on recommendation by PTC for intolerance to standard therapy.
REVIEW INDICATORS
- New efficacy data or reduction in cost.
DATE RATIFIED
- 31 March 2016
INDICATIONS AND NEMLC RECOMMENDATIONS 2
INDICATION
- Rheumatoid Arthritis where patients are intolerant or have contraindications to methotrexate and sulphasalazine.
NEMLC RECOMMENDATION
- Approved
Only for use in patients with intolerance to standard DMARD therapy (methotrexate or sulphasalazine)
REVIEW INDICATORS
- New evidence.
- Safety concerns.
- Price change.
DATE RATIFIED
- 12 April 2018